List of Excipients in Branded Drug ONGENTYS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	FD&C BLUE NO. 2	2030-03-31
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	FD&C RED NO. 3	2030-03-31
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	GELATIN	2030-03-31
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	LACTOSE	2030-03-31
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	MAGNESIUM STEARATE	2030-03-31
Amneal Pharmaceuticals LLC	ONGENTYS	opicapone	64896-402	SODIUM STARCH GLYCOLATE TYPE A POTATO	2030-03-31

Ongentys Excipient Strategy and Commercial Opportunities for Opicapone

Last updated: August 13, 2026

Ongentys is a once-daily oral opicapone capsule approved in the United States as an adjunct to levodopa/carbidopa for adults with Parkinson's disease experiencing "off" episodes. Its commercial formulation has a relatively simple immediate-release excipient system: lactose monohydrate, disintegrants, magnesium stearate, and hard-gelatin capsule components. The most attractive excipient opportunities are therefore not complex delivery technologies. They are lower-cost generic substitution, lactose-free reformulation, capsule-shell differentiation, fixed-dose combinations, and manufacturing controls that preserve dissolution and bioequivalence.

Ongentys has no biosimilar pathway because opicapone is a small molecule. Competitive entry would occur through an Abbreviated New Drug Application, typically with Paragraph IV patent certification where applicable. The main commercial barrier is clinical positioning and physician adoption, not formulation complexity.

What is Ongentys and how is opicapone formulated?

Ongentys contains opicapone, a selective catechol-O-methyltransferase inhibitor. It is administered once daily, generally at bedtime and at least one hour before or after food, in 25 mg and 50 mg strengths. The drug is used with levodopa/carbidopa to extend levodopa exposure and reduce motor "off" time. [1]

Ongentys dosage forms and strengths

Attribute	Ongentys detail
Active ingredient	Opicapone
Dosage form	Immediate-release hard gelatin capsule
Strengths	25 mg and 50 mg
Administration	Once daily
Therapeutic use	Adjunct to levodopa/carbidopa in Parkinson's disease
U.S. approval	FDA approval in 2020
U.S. commercial rights	Neurocrine Biosciences
Originator	BIAL
Generic pathway	ANDA, not biosimilar

The U.S. prescribing information identifies lactose monohydrate, croscarmellose sodium, and magnesium stearate among the inactive ingredients. The capsule shell contains gelatin and colorants, including titanium dioxide and iron oxides; the precise colorant profile varies by strength. [1]

The formulation has no polymeric extended-release matrix, lipid vehicle, enteric coating, osmotic system, or injectable delivery platform. That structure reduces manufacturing complexity and lowers the technical barrier to generic development.

What excipients are used in Ongentys capsules?

The core excipient strategy performs three conventional functions:

1. Lactose monohydrate provides bulk and improves powder handling.
2. Croscarmellose sodium promotes capsule disintegration.
3. Magnesium stearate lubricates the blend and supports encapsulation.

The hard-gelatin shell provides physical containment, identification by color, and patient handling. Because the product is an immediate-release capsule, the critical quality attributes are likely to include assay, content uniformity, impurities, disintegration, dissolution, moisture, and stability.

Excipient-function analysis

Excipient or component	Primary function	Commercial implication
Lactose monohydrate	Diluent and filler	Low cost, broad availability; creates lactose-intolerance positioning opportunity
Croscarmellose sodium	Superdisintegrant	Supports rapid capsule opening and dissolution
Magnesium stearate	Lubricant	Excessive use may slow wetting or dissolution
Gelatin	Capsule shell	Standard hard-capsule platform; animal-origin and vegetarian alternatives are possible
Titanium dioxide and iron oxides	Opacity and color	Supports strength differentiation and product identification

The main formulation sensitivity is the balance between lubrication and dissolution. Magnesium stearate can create hydrophobic particle surfaces when used at excessive levels or blended for too long. A generic manufacturer may change grade, concentration, or blending time, but the final product must maintain comparable dissolution and bioequivalence.

Lactose also creates a practical development issue. Lactose monohydrate is inexpensive and widely qualified, but some patients avoid lactose or report intolerance. A lactose-free version could replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent. That change would not automatically create meaningful clinical differentiation, but it could support a targeted product claim if the formulation, labeling, and regulatory package substantiate the distinction.

What formulation patents protect Ongentys?

Ongentys protection is primarily associated with opicapone composition, pharmaceutical use, dosage, and related product claims rather than a proprietary excipient platform. The marketed capsule does not depend on a visibly complex delivery system that would create a strong formulation moat.

FDA Orange Book information should be reviewed for the current patent listings and expiration data tied to the approved Ongentys product. [2] Relevant patent analysis should distinguish:

• Active-ingredient composition claims covering opicapone or related chemical forms.
• Method-of-use claims covering adjunctive treatment with levodopa/carbidopa.
• Dose and administration claims covering once-daily use.
• Pharmaceutical-composition claims covering opicapone formulations.
• Manufacturing or process claims that may affect active-ingredient supply.

A generic company cannot assume that replacing an excipient avoids all listed patents. A claim directed to a pharmaceutical composition may cover the active ingredient with a defined excipient class or concentration range. Conversely, an excipient substitution may avoid a narrow formulation claim if the substitute falls outside the claimed composition.

How strong is the Ongentys formulation patent estate?

The formulation estate appears less commercially restrictive than estates built around controlled-release tablets, spray-dried dispersions, lipid systems, or device-based delivery. The main formulation risks are:

• A composition claim broad enough to cover standard capsule excipients.
• A method-of-use claim covering the approved adjunctive indication.
• Patent claims that capture dosage timing or treatment of motor fluctuations.
• Manufacturing patents controlling a commercially practical route to high-purity opicapone.

For generic planning, the key question is not whether the brand uses lactose or croscarmellose sodium. It is whether the proposed product infringes any Orange Book-listed composition or use claim after excipient substitution.

When does Ongentys lose exclusivity?

Ongentys lost regulatory new-chemical-entity exclusivity in the United States in 2024, four years after its 2020 approval. That date does not establish generic availability because patent certifications, litigation, pediatric exclusivity, or settlement terms can delay launch. [1,2]

Ongentys exclusivity timeline

Event	Timing
FDA approval	2020
Standard NCE exclusivity	Through approximately 2024
ANDA filing opportunity	Generally available after the NCE exclusivity barrier, subject to FDA rules
Generic launch	Depends on patent certifications, litigation, settlement, and regulatory approval
Biosimilar exposure	Not applicable

The commercial launch date for a generic depends on the earliest enforceable patent barrier and the outcome of any Paragraph IV litigation. A first filer that successfully challenges relevant patents may obtain 180 days of generic exclusivity under the Hatch-Waxman framework. [3]

What Paragraph IV challenges could affect Ongentys generic entry?

A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed ANDA product. If the brand or patent owner files an infringement action within the statutory period, FDA approval may be stayed for up to 30 months, subject to court action and statutory exceptions. [3]

For Ongentys, a generic applicant would likely evaluate:

• Whether the ANDA product uses the same active moiety and salt or polymorphic form.
• Whether the proposed capsule composition falls within any listed formulation claim.
• Whether the labeling induces infringement of method-of-use claims.
• Whether a skinny label can omit protected indications or dosing instructions.
• Whether the manufacturing process implicates unlisted or non-Orange-Book patents.

A lactose-free or vegetarian-shell product may provide a formulation design-around, but it does not remove the need for a complete patent claim chart.

What excipient substitutions offer the best commercial opportunities?

Lactose-free Ongentys generic

Lactose replacement is the clearest patient-facing opportunity. Candidate diluents include microcrystalline cellulose, mannitol, and dibasic calcium phosphate. The best candidate would depend on powder flow, capsule fill weight, dissolution, moisture sensitivity, and compatibility with opicapone.

A lactose-free claim could help a generic manufacturer compete in specialty-pharmacy channels, although the market may not support a substantial premium without evidence of patient preference or adherence benefit.

Vegetarian or hydroxypropyl methylcellulose capsules

Replacing gelatin with hydroxypropyl methylcellulose or another vegetarian capsule shell could address animal-origin restrictions and expand suitability for certain markets. The change introduces technical work involving:

• Shell moisture transmission.
• Brittleness and mechanical integrity.
• Fill-shell compatibility.
• Disintegration across storage conditions.
• Color matching and capsule identification.

This is a moderate differentiation opportunity, not a high barrier to entry.

Color and strength differentiation

The 25 mg and 50 mg strengths use capsule color to reduce medication errors. A generic may use different colors subject to FDA labeling and trademark constraints. Color selection must preserve strength differentiation without creating look-alike risk against levodopa/carbidopa products or other Parkinson's medicines.

Taste-masked or alternative oral dosage forms

Opicapone is marketed as a swallowed capsule, so taste masking is not a central requirement. Tablets, sprinkle capsules, orally disintegrating tablets, and liquid formulations could create convenience advantages, but each would require new product development and potentially a separate regulatory strategy. The clinical value may be limited because the target population is adult and the existing dosage frequency is once daily.

What manufacturing and excipient barriers affect generic Ongentys?

The principal manufacturing risk is not capsule filling. It is maintaining a reproducible active pharmaceutical ingredient and dissolution profile at low dose.

The 25 mg capsule contains a relatively small active load compared with total fill weight. That creates content-uniformity risk, especially when the active ingredient has different particle-size distribution, density, electrostatic behavior, or flow characteristics from the reference product.

Key process controls include:

• API particle-size distribution.
• Ordered blending and segregation control.
• Blend uniformity.
• Lubrication time and magnesium stearate concentration.
• Capsule-fill weight.
• Dissolution across multiple media and agitation conditions.
• Moisture control for the capsule shell and blend.
• Impurity and degradation-product monitoring.

A contract development and manufacturing organization with low-dose encapsulation capability could compete by offering a faster formulation-development package, analytical method transfer, and scale-up support. Excipient suppliers could target direct supply agreements for pharmaceutical-grade lactose, croscarmellose sodium, capsule shells, and color systems, but these are generally multi-source materials with limited pricing power.

What licensing deals affect Ongentys?

BIAL granted Neurocrine U.S. rights to opicapone, including Ongentys commercialization in the United States. Neurocrine received commercialization rights under a license arrangement while BIAL retained interests outside the licensed territory. [4]

The licensing structure creates opportunities for:

• Regional commercialization outside the United States.
• Local generic or branded-generic partnerships after patent expiry.
• Co-development of lactose-free or alternative-shell products.
• Manufacturing supply agreements for approved-market products.
• Portfolio combinations with levodopa/carbidopa or other Parkinson's therapies.

A prospective partner would need to separate territorial rights, patent rights, regulatory ownership, pharmacovigilance obligations, and supply commitments. An excipient-led reformulation is commercially more likely to proceed as a generic or line-extension strategy than as a stand-alone licensing asset.

What is the FDA and Orange Book status of Ongentys?

Ongentys is FDA-approved and listed as a prescription drug in the Orange Book. The relevant regulatory reference product is the approved 25 mg and 50 mg capsule product. [1,2]

There is no biosimilar pathway. Opicapone is a synthetic small molecule, so competitors would file ANDAs or, for materially different dosage forms or clinical claims, potentially 505(b)(2) applications.

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. Excipients may differ, but the differences must not affect safety, efficacy, manufacturing performance, or bioequivalence.

Which companies are challenging Ongentys?

Publicly visible competition should be tracked through FDA ANDA approvals, Paragraph IV notices, district-court dockets, and patent litigation databases. Generic companies with Parkinson's portfolios, specialty-generic capabilities, or capsule manufacturing capacity are the most likely entrants.

No biosimilar companies are relevant. The likely competitive groups are:

• Large generic manufacturers with established neurology portfolios.
• Specialty-generic companies focused on complex patent work.
• Regional pharmaceutical companies seeking branded generics.
• Contract manufacturers partnering with ANDA sponsors.

The absence of a complex delivery system lowers technical entry barriers. Patent litigation and market size are more important than excipient know-how.

How does Ongentys compare with competing Parkinson's treatments?

Product	Active ingredient	Dosing role	Formulation complexity	Excipient opportunity
Ongentys	Opicapone	Once-daily COMT inhibitor adjunct	Low to moderate	Lactose-free, capsule-shell, generic substitution
Comtan	Entacapone	COMT inhibitor adjunct	Immediate-release tablet	Tablet excipient and combination-product opportunities
Stalevo	Levodopa/carbidopa/entacapone	Fixed-dose combination	Multi-API tablet	Greater content-uniformity and stability complexity
Tasmar	Tolcapone	COMT inhibitor adjunct	Immediate-release tablet	Limited commercial relevance due to safety monitoring
Rytary	Levodopa/carbidopa	Extended-release therapy	Modified-release bead system	Higher formulation barrier

Ongentys has a convenience advantage over multiple daily entacapone dosing, but the formulation itself does not create the same barrier as extended-release levodopa products. A generic opicapone capsule could compete primarily on price, formulary access, supply reliability, and patient assistance.

What revenue exposure and commercial upside does Ongentys have?

Neurocrine's public reporting emphasizes Ingrezza as its lead commercial product and does not consistently present Ongentys as a separately disclosed major revenue line. [5] That limits precise revenue-exposure analysis from public company filings.

The commercial opportunity is still material within the Parkinson's adjunct market because Ongentys addresses a defined treatment problem: motor fluctuations in patients already receiving levodopa/carbidopa. The addressable opportunity depends on:

• Number of levodopa-treated patients with "off" episodes.
• Uptake relative to entacapone and other COMT inhibitors.
• Payer coverage.
• Generic launch timing.
• Price erosion after competition.
• Persistence and adherence associated with once-daily dosing.

For excipient suppliers, the opportunity is recurring but modest on a per-patient basis. The larger value sits with the ANDA sponsor that controls formulation, regulatory approval, manufacturing, and payer contracting.

What generic launch scenarios exist for Ongentys?

Scenario 1: Single generic capsule

A conventional 25 mg and 50 mg capsule using a close excipient system is the lowest-cost entry strategy. It offers the fastest path to ANDA submission but provides little differentiation.

Scenario 2: Lactose-free generic

A lactose-free product can target patients and prescribers seeking excipient exclusions. It may command limited preference in specialty channels but requires new formulation and comparative dissolution work.

Scenario 3: Vegetarian-shell generic

A vegetarian capsule can support market access in selected regions and institutional channels. The commercial impact depends on payer and pharmacy substitution practices.

Scenario 4: Authorized generic or branded generic

A licensed or authorized generic could preserve supply continuity and use established regulatory data. The economics depend heavily on royalty rates, territory, and the timing of patent settlements.

Key Takeaways

• Ongentys uses a conventional immediate-release hard-gelatin capsule with lactose monohydrate, croscarmellose sodium, and magnesium stearate.
• The formulation is relatively easy to reproduce compared with modified-release or device-based Parkinson's products.
• The most practical excipient opportunities are lactose-free diluents, vegetarian capsule shells, and improved low-dose blend uniformity.
• Ongentys is a small-molecule drug, so generic competition proceeds through ANDA filings rather than biosimilar applications.
• NCE exclusivity ended approximately four years after the 2020 FDA approval, but patent and litigation outcomes control actual generic launch timing.
• The strongest commercial asset is once-daily clinical positioning, not a complex excipient or delivery platform.
• Excipient suppliers face a large-volume but low-margin opportunity; ANDA sponsors capture most of the value through regulatory approval and market access.

FAQs

Can opicapone be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, or another compatible diluent. The substitute must support content uniformity, dissolution, stability, and bioequivalence.

Is Ongentys an extended-release formulation?

No. Ongentys is an immediate-release capsule, although its once-daily clinical effect reflects opicapone pharmacology and COMT inhibition rather than a modified-release excipient system.

Can a generic Ongentys use a different capsule shell?

Yes. A generic may use a different capsule-shell composition or color if the product meets regulatory requirements and does not create labeling, identification, stability, or bioequivalence problems.

Does a lactose-free Ongentys avoid patent infringement?

Not necessarily. Patent claims may cover the active ingredient, dosage, method of use, or broad pharmaceutical compositions. Excipient substitution must be evaluated against each relevant claim.

Is there a commercial opportunity for an opicapone fixed-dose combination?

Potentially. A fixed-dose product with levodopa/carbidopa could improve pill burden, but it would introduce substantial formulation, dose-flexibility, stability, and regulatory challenges. A 505(b)(2) or other application strategy could be required depending on the product design.

References

1. U.S. Food and Drug Administration. (2020). Ongentys (opicapone) capsules: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). 180-day exclusivity for generic drug products.
4. Neurocrine Biosciences, Inc. (2017). Neurocrine enters into exclusive U.S. license agreement with BIAL for opicapone.
5. Neurocrine Biosciences, Inc. (2024). Annual report on Form 10-K.